Spirea is at the forefront of revolutionising cancer and beyond with our cutting-edge ELIVATE linker technology.
Our innovative approach significantly expands the payload repertoire for antibody-drug conjugates (ADCs), enabling the next generation of targeted therapies. By leveraging ELIVATE’s multivalent capabilities, we optimise therapeutic outcomes, ensuring precise drug delivery and enhanced pharmacokinetics.
Our dedicated team of experts is committed to advancing our proprietary ADC pipeline and forming strategic partnerships to maximise the potential of our technology. Join us on our mission to transform patient care and deliver groundbreaking treatments across a wide range of diseases.
Explore how Spirea is unlocking the full potential of ADCs at www.spirea.co.uk
Company Details
- Employees
- 8
- Address
- Cambridge, 1853, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- spirea.co.uk
- HQ
- Cambridge
Spirea Questions
Spirea's website is spirea.co.uk
Spirea's LinkedIn profile is https://uk.linkedin.com/company/spirea
Spirea has
8 employees.
View email and phone details for 8
employees at Spirea.
Spirea's industry is
Biotechnology Research
Spirea's top competitors are
T-Therapeutics Ltd,
Pharmenable Therapeutics,
Qkine,
Concr,
Biomodal,
Storm Therapeutics Limited,
Astex Pharmaceuticals,
Verinnogen,
52north - Creators Of Neutrocheck®,
Phoremost Ltd.
Spirea's categories are Biotechnology Research
